Feasibility of Novel Slim Peroral Cholangiopancreatoscopy for the Diagnosis of Pancreatobiliary Disease
Haruo Miwa(Yokohama City University Medical Center), Shin Maeda(Yokohama City University), Yuichi Suzuki(Yokohama City University Medical Center), Yoshimasa Suzuki(Yokohama City University Medical Center), Yugo Ishino(Yokohama City University Medical Center), Yoshihiro Goda(Yokohama City University Hospital), Hideyuki Anan(Yokohama City University Hospital), Akihiro Funaoka(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Shotaro Tsunoda(Yokohama City University Medical Center), Ritsuko Oishi(Yokohama City University Medical Center), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Kuniyasu Irie(Yokohama City University Hospital), Kazuki Endo(Yokohama City University Medical Center), Takashi Kaneko(Yokohama City University Medical Center), Hiromi Tsuchiya(Yokohama City University Medical Center), Kazuya Sugimori(National Cancer Center Hospital East)
Cited by 4
Related Papers
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
|Annals of Oncology|2019|333
Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
|Journal of Gastroenterology|2017|91